MedTrace Logo

Mumbai Worksite Tobacco Control Study

NCT01841879 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6880

Last updated 2017-04-17

No results posted yet for this study

Summary

The investigators are designing and testing the effectiveness of an integrated tobacco control and occupational health (OH) intervention aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies in 20 manufacturing worksites in the greater Mumbai region of India.

Conditions

  • Tobacco Use Cessation

Interventions

BEHAVIORAL

Intervention Program

Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies. Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use. Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced.

BEHAVIORAL

Delayed Intervention

Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Healis-Sekhsaria Institute for Public Health

    collaborator OTHER

  • Carelon Research

    collaborator OTHER

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    lead OTHER

Principal Investigators

  • Glorian Sorensen, PhD, MPH · Harvard School of Public Health, Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841879 on ClinicalTrials.gov